Keeping Track: AZ’s Imjudo, J&J’s Tecvayli Enter Burgeoning Immuno-Oncology Market; Genmab Submits Epcoritamab
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
Organs On Chips: The Silver Bullet Pharma Is Priming To Fire
In this two-part series, In Vivo will explore why organ on chip technology exists, the factors driving and limiting their application in drug development, and how companies can benefit from using them.
AstraZeneca CTLA-4 Inhibitor Imjudo (Finally) Wins FDA Approval
More than a decade after Pfizer gave up on it, tremelimumab won approval combined with PD-L1 inhibitor Imfinzi for frontline hepatocellular carcinoma, ahead of Bristol’s Yervoy/Opdivo second-line indication.
Sponsors Want Answers On Consequences Of Missing US FDA Trial Diversity Goals
No negative actions have been taken in the US FDA’s oncology review divisions, but vague diversity guidance continues to raise concerns.